曲罗芦单抗(Tralokinumab) - 药物靶点：IL-13_在研适应症：皮炎，特应性皮炎_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

tralokinumab-ldrm、BAK-502G9、CAT-354

+ [4]

靶点

IL-13

作用机制

IL-13抑制剂(白细胞介素-13抑制剂)

治疗领域

免疫系统疾病遗传病与畸形皮肤和肌肉骨骼疾病

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

最高研发阶段批准上市

首次获批日期

欧盟 (2021-06-17),

特应性皮炎

最高研发阶段(中国)-

特殊审评-

登录后查看首次获批时间轴

序列信息

Sequence Code 13007322H

来源: *****

Sequence Code 13007734L

来源: *****

关联

49

项与曲罗芦单抗相关的临床试验

NCT06311682 / Recruiting临床3期

A Phase 3 Multi-center Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children (Age 2 to <12 Years) and Infants (Age 6 Months to <2 Years) With Moderate-to-severe Atopic Dermatitis. The Trial is Randomized, Double-blind, Placebo-controlled, and Parallel-group for Children (Age 2 to <12 Years) and Open-label and Single-group for Infants (Age 6 Months to <2 Years)

The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections [SC]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic dermatitis (AD) in children and infants. This will be judged by a range of assessments that rate the severity and extent of atopic dermatitis and its symptoms, as well as general health status and quality of life. The trial will last for up to 4 years. There will be visits every 2 weeks for the first year and every 6 weeks thereafter. Some of the visits will be conducted by phone.
The study involves two different age groups: children aged 2 to under 12 years and infants aged 6 months to under 2 years. This trial compares tralokinumab +TCS to placebo + TCS for children with moderate-to-severe AD and evaluates tralokinumab + TCS for infants with moderate-to-severe AD. Infants will not receive placebo. All subjects will go through a screening process, which is the first part of the trial and will last up to 4 weeks. During this period, it will be checked if the child or infant meets the criteria to participate in the trial.
The children will be randomly assigned to receive tralokinumab + TCS or placebo + TCS for the initial 16 weeks, with the treatment being double-blinded. During the first 16 weeks, children will have a 2 out of 3 chance of getting tralokinumab and a 1 out of 3 chance of getting placebo. Thereafter, all subjects will receive tralokinumab + TCS. The infants will receive tralokinumab + TCS as open-label treatment for the entire treatment period, meaning that the participants will know they are receiving tralokinumab. After stopping treatment, all participants will enter a 4-week safety follow-up period.

开始日期2024-06-10

申办/合作机构

Leo Pharma, Inc.

NCT06366932 / Recruiting临床4期

Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Multiomic Predictive Models of Treatment Response (DermAtOmics-II)

This is a low-intervention phase IV trial. The main objective is to optimize the treatment of patients with moderate-severe atopic dermatitis that require systemic treatment after failure, intolerance or contraindication to cyclosporine.

开始日期2023-09-25

申办/合作机构

Hospital Universitario La Paz

NCT05958407 / Recruiting临床3期

A Phase 3b, Interventional, Adaptive, Clinical Trial to Evaluate the Efficacy and Safety of Tralokinumab 300 mg Every Second Week Monotherapy Compared With Placebo in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy

The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life.
The trial will last for up to 40 weeks. There will be up to 15 visits, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to 4 weeks. For the first 16 weeks after screening, trial participants will receive either tralokinumab or dummy injections every two weeks. After the first 16 weeks, all trial participants will receive tralokinumab injections every two weeks for 16 weeks. The last part of the trial is a period of 4 weeks after the end of treatment period, where trial participants are off the drug for safety follow-up.

开始日期2023-08-28

申办/合作机构

Leo Pharma, Inc.

100 项与曲罗芦单抗相关的临床结果

登录后查看更多信息

100 项与曲罗芦单抗相关的转化医学

登录后查看更多信息

100 项与曲罗芦单抗相关的专利（医药）

登录后查看更多信息

195

项与曲罗芦单抗相关的文献（医药）

2024-12-31·The Journal of dermatological treatment

Injection site reactions after dupilumab or tralokinumab for atopic dermatitis

Article

作者: Martora, Fabrizio ; D'Ascenzo, Silvia ; Napolitano, Maddalena ; Patruno, Cataldo

Background: Injection site reaction (ISR) is a local phenomenon defined as a constellation of symptoms, including swelling, erythema, pruritus, and pain around the site of injection.Objective: ISR is reported as a frequent adverse event after subcutaneous injection (SCI) of several biologics.Methods: We performed an observational real-life study to compare dupilumab and tralokinumab as regards ISR, analysing frequency, duration and intensity of symptoms related to SCI. From January 2023 to June 2023, we enrolled adult patients affected by moderate to severe AD and being on dupilumab or tralokinumab treatment. A 12 items questionnaire was administered to all enrolled patients.Results and conclusions: Three hundred and ninety-two patients were included. ISR was a frequent occurrence in both the treatment groups, with tralokinumab causing ISR more frequently than dupilumab. However, the reactions were generally mild and no patient stopped therapy.

2024-03-03·Expert review of clinical immunology

A critical evaluation of suitability of tralokinumab for treatment of moderate-to-severe atopic dermatitis in adolescents and adults

Review

作者: Naldi, Luigi ; Pezzolo, Elena ; Sechi, Andrea ; Tartaglia, Jacopo

INTRODUCTION:

Atopic dermatitis (AD) is a chronic, intensely pruritic disease associated with significant patient burden. Recent advancements in AD pathogenesis have expanded its therapeutics pipeline. Tralokinumab is a fully human monoclonal antibody that binds specifically Interleukin (IL)-13, inhibiting the downstream IL-13 signaling. Phase 3 clinical trials and some real-world studies showed that tralokinumab, as monotherapy or in combination with topical corticosteroids, is efficacious and safe in adult patients with moderate-to-severe AD. Similar results were reported in a phase 3 trial in adolescents (aged ≥12 years).

AREAS COVERED:

We review the role of IL-13 in AD and discuss the value of tralokinumab for treating moderate-to-severe AD, comparing efficacy and safety results derived from clinical trials and real-life data.

EXPERT OPINION:

The role of IL-13 in AD supports a targeted therapeutic approach. Tralokinumab has proven efficacious and well-tolerated in a large proportion of patients confirming its value for treating moderate-to-severe AD from age 12 years onwards; it quickly improves itching and can maintain a high-level of response over time; it can be administered with flexible dosing schedules. Future studies will further clarify the role of IL-13 pathway and which patients would be best suited to tralokinumab, shifting AD treatment into an era of precision medicine.

2024-03-01·Journal of the European Academy of Dermatology and Venereology : JEADV

Tralokinumab improves clinical scores in adolescents with severe atopic dermatitis: A real‐life multicentric observational study

Letter

作者: Adriaenssens, Kristel ; Cuvelier, Marie ; Stragier, Ilse ; Bulinckx, Audrey ; Baeck, Marie ; Kul, Anouschka ; Deleu, Hilde ; Colmant, Caroline ; De Greef, Axel ; Ghislain, Pierre-Dominique ; Janssens, Pauline ; Goeteyn, Marleen ; de Montjoye, Laurence ; Roquet-Gravy, Charlotte

44

项与曲罗芦单抗相关的新闻（医药）

2024-06-13

·Pharmaceutical Technology

Leo’s single-dose autoinjector secures FDA approval for atopic dermatitis

Adbry targets the cytokine IL-13, which drives inflammatory processes of symptoms commonly seen in atopic dermatitis. Credit: Pormezz / Shutterstock. Leo Pharma has announced that its injection treatment for atopic dermatitis, Adbry (tralokinumab-ldrm), will gain an alternative mode of administration following a US Food and Drug Administration (FDA) approval for its single-dose autoinjector. Recommended Buyer's Guides Buyer's Guide Leading Guide to Packaging Materials, Containers and Containment Services for the Pharmaceutical Industry Buyer's Guide Top Guide for Drug Delivery Systems Adbry targets interleukin-13 (IL-13), a cytokine that drives inflammatory processes associated with the symptoms of atopic dermatitis. Adbry is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies, following a December 2021 approval. According to GlobalData’s consensus forecasts, Adbry is expected to generate global sales of $1.3bn in 2030. The treatment produced net global sales of $106m in 2023. GlobalData is the parent company of Pharmaceutical Technology . As per the 13 June press announcement, the treatment will now be available for adult patients as a 300 mg/2 mL single dose autoinjector treatment as another option to the existing 150 mg/1 mL pre-filled injectable, which will continue to be available in the US. Leo Pharma is taking steps to make the newly approved device available to US patients in the coming months, EVP and President, Region North America at Leo Pharma, Brian Hilberdink said in the press release. “We understand that no patient is the same, and through this extended approval we have taken a positive step forward to equip those living with atopic dermatitis with more choices,” said Shannon Schneider, Senior Medical Affairs Director at LEO Pharma. See Also: NPX-267 by NextPoint Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval PF-07960613 by Pfizer for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval Ballerup, Denmark-based LEO is not the only pharma making strides in the atopic dermatitis space. As per a GlobalData report , the atopic dermatitis market is predicted to be worth $24.4bn across the 61 geographical markets in 2030, with 71.8% of that coming from the seven major markets of US, France, Germany, Italy, Spain, UK, and Japan.” Earlier in the week, Denmark-based Union Therapeutics shared positive data from its Phase IIb ADESOS study (NCT05469464) which evaluated orismilast as an oral treatment for moderate- to-severe atopic dermatitis. Union is looking to initiate a Phase III programme and has reached out to the FDA with initial plans. Also in the picture is Dermavant’s nonsteroidal topical nonsteroidal, VTAMA (tapinarof), which received FDA acceptance for its supplemental New Drug Application (sNDA). According to GlobalData’s analysts, atopic dermatitis presents a mine of opportunities , particularly for drugs that target AhR due to the low rate of adverse effects seen in previous clinical trials.

临床结果上市批准临床2期临床3期

2024-06-12

·BioSpace

Adtralza® (tralokinumab injection) Pre-Filled Pen Now Available in Canada

The single-use 2 mL pre-filled pen is an additional injection choice for administering Adtralza for the treatment of moderate-to-severe atopic dermatitis (AD).1 The new Adtralza (tralokinumab injection) pre-filled pen means patients can administer their prescribed dose with half the number of injections, and also simplifies the process, with a hidden needle and press-down auto-injection.1 Adtralza is currently indicated in patients 12 years and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.1 TORONTO--(BUSINESS WIRE)-- LEO Pharma Inc. today announced the availability of the Adtralza® (tralokinumab 300 mg/2 mL) pre-filled pen in Canada. Adtralza is currently indicated in patients 12 years and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.1 Prior to the introduction of the pre-filled pen, Adtralza was only available in a 1 mL pre-filled syringe. With the new 2 mL pre-filled pen, patients now have another convenient option with half the number of required injections compared to the 1 mL pre-filled syringe.1 “The pre-filled pen simplifies the injection process and can be helpful for those who are uncomfortable with the sight of needles,” said Dr. Chih-ho Hong, M.D., board certified dermatologist working in Greater Vancouver, BC, and national coordinating investigator for ECZTRA 6 trial in Canada. “It also means half the number of required injections. This option can help reduce patient treatment burden significantly.” “Atopic dermatitis can be difficult to manage, and can feel overwhelming,” said Amanda Cresswell-Melville, Executive Director, Eczema Society of Canada. “More treatment options mean more hope to those impacted by this burdensome condition.” “We are pleased to offer Canadians with moderate-to-severe AD an additional option with the single-use pre-filled pen,” said Jill Archibald, President and CEO, LEO Pharma Inc., Canada. “LEO Pharma is committed to supporting patients and providing them with options that offer convenience and help meet their treatment goals.” For patients who prefer the pre-filled syringe, this option will continue to be available in Canada. About Adtralza® (tralokinumab injection) Adtralza is a human, monoclonal antibody developed to specifically target the IL-13 cytokine, which plays a key role in the immune process underlying atopic dermatitis signs and symptoms. Adtralza specifically binds to the IL-13 cytokine with high affinity, thereby inhibiting interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL-13Rα2).1 In Canada, Adtralza is available in a single-use pre-filled syringe (150 mg/1 mL) as well as a single-use pre-filled pen (300 mg/2 mL). Adtralza received approval from Health Canada in October 2021, for the treatment of moderate to severe atopic dermatitis in adults. Subsequently, in February 2023, the indication was expanded to include adolescents aged 12 – 17 years. The pre-filled pen received approval in August 2023.1 For more information, please refer to the Canadian product monograph for Adtralza located here. About Atopic Dermatitis/Eczema Eczema is a chronic inflammatory skin condition, characterized by dry skin, with patches that are red and intensely itchy. These patches of eczema may ooze, become scaly, crusted, or hardened. The condition can impact the patient’s quality of life negatively, as symptoms can range mild to severe. While eczema can appear anywhere on the skin, it is commonly found on the flexor areas, such as the bends of the arms and back of the knees.2 Out of the several types of eczema, atopic dermatitis is the most common. Atopy refers to the genetic susceptibility towards eczema, asthma and allergic rhinitis (hay fever). People with AD can also suffer from one of the other atopic diseases. 2 About LEO Pharma LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,200 people, serving millions of patients across the world. For more information, please visit . Adtralza® and the LEO Lion logo are registered trademarks of LEO Pharma A/S used under license and distributed by LEO Pharma Inc. Canada. ___________________________ LEO Pharma. Product Monograph: Adtralza®. Toronto, ON. 2023. Eczema Society of Canada. What is eczema? Eczema Overview. Accessed June 6, 2024 MAT-74087 June 2024 View source version on businesswire.com: Contacts Melissa Borland LEO Pharma, Senior Manager Communications, North America 647.241.1475 MQBCA@leo-pharma.com Jes Broe Frederiksen LEO Pharma, Global Communications Manager, Corporate Affairs Tel: +45 53 60 59 48 Email: jebfe@leo-pharma.com Source: LEO Pharma Inc. View this news release online at:

上市批准

2024-05-29

·精准药物

阿斯利康1.5亿美元贱卖FIC新药，接手公司股价翻倍

REFACE前言DPP-4已成为全球降糖药市场的主力军，同属DPP家族的DPP-1则有望在炎症疾病治疗领域创出一片天。先前研究表明，在慢性炎症性肺病中，中性粒细胞在气道中聚集并导致中性粒细胞丝氨酸蛋白酶过度活跃，从而引起肺组织损伤和炎症。而DPP-1又是负责激活中性粒细胞中的中性粒细胞丝氨酸蛋白酶，因此抑制DPP-1有望降低炎症性疾病的组织损伤。目前，针对DPP-1靶点的主要开发方向是支气管扩张症，历史上已经进入临床阶段的DPP-1抑制剂共有4款，其中Insmed手上的DPP-1抑制剂brensocatib近期临床3期试验取得成功，Insmed股价当天翻倍；BI的BI1291583和海思科的HSK31858均处于临床2期，其中海思科的海外权益已经授权给了Chiesi；GSK的GSK-2793660则是命途多舛，已经于2015年折戟临床后被舍弃。01阿斯利康1.5美元卖掉的药三期成功2008年，阿斯利康全球收入增速放缓，此后的2012年至2018年，阿斯利康收入持续下滑，期间更是收到过辉瑞的收购要约，陷入下降通道的阿斯利康命悬一线。彼时的阿斯利康，快速调整核心业务板块和战略方向迫在眉睫，因而在此期间，阿斯利康不断优化产品结构，剥离非核心业务，从而谋求战略转型的成功。尤其是在2016年，阿斯利康批量“甩卖”。据公开信息显示，当年阿斯利康共达成了十余次“卖子”的合作，其中包括把处于临床后期的小分子抗感染药物打包出售给辉瑞，把tralokinumab和brodalumab卖给了LEO pharma，以及把DPP-1抑制剂AZD7986以1.5亿美元的金额出售给了Insmed等等。其中，值得一提的是，阿斯利康只卖了1.5亿美元的DPP-1抑制剂AZD7986（Brensocatib），近期关键临床试验取得了成功，离商业化仅一步之遥了。根据Insmed新闻稿显示，brensocatib治疗非囊性纤维化支气管扩张症（NCFBE）的临床三期ASPEN研究取得了成功。ASPEN是一项全球性的随机、双盲、安慰剂对照的临床3期研究，旨在评估brensocatib在NCFBE患者中的疗效、安全性和耐受性，结果显示，在主要终点方面，两个剂量组（10mg和25mg）的肺急性加重（PEs）的年发生率相比于安慰剂组，分别下降了21.1%和19.4%，下降明显，并且该研究还达到了多个次要终点。截图自Insmed公开文件在安全性方面，治疗组的TEAE和治疗中止率与安慰剂组相当，Brensocatib在试验中耐受性良好。截图自Insmed公开文件受此消息催化，Insmed当日股价大涨近120%，创造了近20年以来的新高，市值也达到了72亿美元。Insmed股价暴涨，截图自同花顺Insmed在新闻稿中表示，预计将在今年第四季度向FDA递交该适应症的NDA。除支气管扩张适应症以外，Brensocatib还有慢性鼻窦炎（CRSsNP）以及化脓性汗腺炎（HS）等适应在研。目前回首2016年被AZ卖掉的药，其中相当一部分已经取得了成功。如brensocatib有望成为首款获批上市的DPP-1抑制剂，再如卖给LEO pharma的IL-13单抗tralokinumab已经于2021年末获得FDA批准上市，2022年的销售额达到14.3亿丹麦克朗（约为2.1亿美元）。事后来看，阿斯利康卖掉的药物中，不少精品，但如果没有当时的果断，或许也就没有阿斯利康逆袭成功的佳谈了。02GSK落败海思科、BI竞速在全球范围内，DPP-1靶点的竞争并不激烈，除上文所说的brensocatib外，仅有三款药物正处于或曾处于临床阶段，分别为BI的BI1291583、海思科的HSK31858以及GSK的GSK-2793660。对于全新靶点的探索，先行者总会面临更大的阻力与风险，DPP-1也不例外。在阿斯利康选择转让brensocatib的前一年，GSK由于客观原因终止了GSK-2793660的开发。GSK-2793660也成为了首款折戟临床的DPP-1靶点药物，而这或许也在一定程度上影响了阿斯利康对于旗下管线的判断。目前处于临床活跃阶段的三款DPP-1靶点药物，除brensocatib进度领先外，其余两款均处于临床2期。其中海思科的HSK31858是一款口服、强效和高选择性的DPP1抑制剂，在2021年末申报临床，为国内首款。目前，HSK31858支气管扩张适应症即将进入临床3期，COPD、哮喘等适应症已经获临床批件。并且值得一提的是，在2023年11月21日，海思科将HSK31858大中华区（包括港澳台）以外的权益有偿许可给Chiesi集团，总金额为4.62亿美元，是阿斯利康出手时的三倍。截图自BI ANNUAL REPORT 2023BI的BI1291583目前针对NCFBE正处于处于临床2期，有研究表明，BI1291583以共价、可逆的方式结合人DPP-1并高效抑制DPP-1活性。声明：发表/转载本文仅仅是出于传播信息的需要，并不意味着代表本公众号观点或证实其内容的真实性。据此内容作出的任何判断，后果自负。若有侵权，告知必删！长按关注本公众号粉丝群/投稿/授权/广告等请联系公众号助手觉得本文好看，请点这里↓

临床3期临床2期并购临床结果

100 项与曲罗芦单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	曲罗芦单抗	D11AH	DB12169

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
皮炎	韩国	Leo Pharma, Inc.	2023-08-31
特应性皮炎	欧盟	LEO Pharma A/S	2021-06-17
特应性皮炎	冰岛	LEO Pharma A/S	2021-06-17
特应性皮炎	列支敦士登	LEO Pharma A/S	2021-06-17
特应性皮炎	挪威	LEO Pharma A/S	2021-06-17

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
湿疹	临床3期	美国	Leo Pharma, Inc.	2018-06-19
湿疹	临床3期	日本	Leo Pharma, Inc.	2018-06-19
湿疹	临床3期	澳大利亚	Leo Pharma, Inc.	2018-06-19
湿疹	临床3期	比利时	Leo Pharma, Inc.	2018-06-19
湿疹	临床3期	加拿大	Leo Pharma, Inc.	2018-06-19
湿疹	临床3期	法国	Leo Pharma, Inc.	2018-06-19
湿疹	临床3期	德国	Leo Pharma, Inc.	2018-06-19
湿疹	临床3期	荷兰	Leo Pharma, Inc.	2018-06-19
湿疹	临床3期	波兰	Leo Pharma, Inc.	2018-06-19
湿疹	临床3期	英国	Leo Pharma, Inc.	2018-06-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03587805 (ECZTEND, EADV2023)	临床3期	特应性皮炎	347	Tralokinumab ± optional topical corticosteroids (TCS)	鹹遞艱顧蓋膚夢遞餘獵(選齋範壓鹹糧窪顧顧蓋) = The safety profile was favorable and consistent with earlier analyses, with no new safety signals arising with continued tralokinumab use 獵鏇糧鬱鏇選築廠糧淵 (顧蓋餘蓋鏇選餘範衊糧 )	-	2023-10-11
EADV2023	N/A	特应性皮炎 IL-13 \| MDC \| CCL17 ... 更多	16	Tralokinumab 300 mg	齋壓鹹構選膚觸鬱鹹選(觸壓廠構醖糧鏇顧鏇艱) = 廠壓製構鏇遞夢築膚蓋餘壓簾簾膚醖艱鑰醖簾 (艱憲獵襯艱鏇餘簾顧簾 ) 更多	积极	2023-10-11
WCD2023	N/A	特应性皮炎	24	Tralokinumab	築襯簾鹽窪簾壓蓋築衊(醖窪廠鑰鹽膚鑰醖遞壓) = 遞齋憲窪廠築餘網廠顧遞齋糧鏇壓憲襯築鹽構 (觸遞齋餘簾憲願獵壓鹽 )	积极	2023-07-03
NCT03526861 (ECZTRA 6, Pubmed)	临床3期	特应性皮炎	301	Tralokinumab 150 mg	網鹹積窪鏇憲餘齋遞鑰(簾壓構鬱觸夢積製簾艱) = Tralokinumab was well tolerated, without frequency of conjunctivitis increasing through week 52. 淵糧製艱廠繭襯膚網膚 (艱遞顧顧積築齋鹹網遞 )	积极	2023-04-19
				Tralokinumab 300 mg
NCT03587805 (ECZTEND, AAD2023)	临床3期	特应性皮炎	289	Tralokinumab 300mg	夢鬱鹽膚獵糧壓壓淵艱(醖餘醖願鑰衊範獵廠蓋) = 鏇淵顧積鬱窪窪選鹽製鏇簾蓋積遞鬱衊憲願構 (積製築製鬱繭構鏇顧顧 ) 更多	-	2023-03-17
				Placebo	夢鬱鹽膚獵糧壓壓淵艱(醖餘醖願鑰衊範獵廠蓋) = 鏇廠廠夢廠築齋鏇鹹構鏇簾蓋積遞鬱衊憲願構 (積製築製鬱繭構鏇顧顧 ) 更多
NCT03363854 \| NCT03160885 \| NCT03131648 (ECZTRA 1, 2, and 3, Pubmed)	临床3期	特应性皮炎	1,596	Tralokinumab	鏇構鹽構構膚夢窪網觸(蓋製積積積鬱繭網鑰夢) = 壓蓋醖顧築積鑰繭繭繭鑰網積鑰鹽憲膚繭鹹遞 (艱廠願觸積襯願艱夢糧, 12.6, 28.7) 更多	积极	2022-09-24
				Placebo	鏇構鹽構構膚夢窪網觸(蓋製積積積鬱繭網鑰夢) = 壓獵糧構簾簾膚鏇選蓋鑰網積鑰鹽憲膚繭鹹遞 (艱廠願觸積襯願艱夢糧 ) 更多
NCT04587453 (CTgov)	临床3期	特应性皮炎	106	Topical corticosteroids (TCS)+Tralokinumab (Tralokinumab+TCS)	獵製齋淵顧艱構憲窪繭(願選壓廠餘餘觸選淵淵) = 憲鏇襯顧積繭廠鬱鏇襯餘簾製壓齋選構製齋構 (網願築鬱淵廠繭顧鹽淵, 獵夢糧鑰鹽窪網積膚醖 ~ 艱壓願積憲壓淵構壓蓋) 更多	-	2022-09-22
				Placebo (Placebo+TCS)	獵製齋淵顧艱構憲窪繭(願選壓廠餘餘觸選淵淵) = 鑰願蓋鹽廠鹹願築鹹範餘簾製壓齋選構製齋構 (網願築鬱淵廠繭顧鹽淵, 糧觸積築簾夢衊鬱築衊 ~ 觸網網獵築醖糧築壓選) 更多
Pubmed	临床2/3期	特应性皮炎	2,285	Tralokinumab	積獵窪繭觸願糧簾範鬱(齋衊壓糧蓋觸夢窪構衊) = 鹹壓壓構廠襯選壓夢淵積鬱繭淵選艱選衊鑰夢 (艱鹽衊醖獵範鹹壓鹽積 ) 更多	积极	2022-09-09
				Placebo	積獵窪繭觸願糧簾範鬱(齋衊壓糧蓋觸夢窪構衊) = 製範願夢夢獵遞蓋願齋積鬱繭淵選艱選衊鑰夢 (艱鹽衊醖獵範鹹壓鹽積 ) 更多
NCT03587805 (ECZTEND, EADV2022)	临床2/3期	特应性皮炎	347	Tralokinumab 300 mg every 2 weeks	廠構夢醖遞膚夢淵遞夢(壓獵築網顧簾積膚窪鹹) = 糧廠醖憲遞壓構夢積鏇襯範壓構淵製鏇願鏇獵 (鏇齋製膚餘願餘願窪蓋 ) 更多	积极	2022-09-07
NCT03363854 (ECZTRA 3, Pubmed) 人工标引	临床3期	特应性皮炎	233	Tralokinumab	窪構顧範積膚網蓋鏇遞(廠積遞鹹簾艱鏇鏇範鬱) = 願鏇蓋願齋鬱膚願夢壓夢糧簾淵廠襯蓋願蓋鬱 (選鏇蓋獵築選構積鹽窪 ) 更多	积极	2022-07-20
				Placebo	製願簾範憲獵構壓鏇窪(淵夢鹽鬱衊鏇範憲蓋夢) = 顧窪餘鹹衊蓋壓獵繭範醖鬱簾壓齋夢壓觸壓鬱 (獵鑰遞觸醖廠窪遞醖醖 )